-
公开(公告)号:US5006651A
公开(公告)日:1991-04-09
申请号:US410779
申请日:1989-09-22
申请人: Michael J. Broadhurst , Balraj K. Handa , William H. Johnson , Geoffrey Lawton , Peter J. Machin
发明人: Michael J. Broadhurst , Balraj K. Handa , William H. Johnson , Geoffrey Lawton , Peter J. Machin
CPC分类号: C07K5/06191 , A61K38/00
摘要: The invention relates compounds of the formula ##STR1## wherein R.sup.1 -R.sup.5 and X have the significance given in the description, and their pharmaceutically acceptable salts. The compounds of formula I inhibit the enzyme collagenase and can be used in the form of medicaments for the control or prevention of degenerative joint diseases such as rheumatoid arthritis and osteoarthritis.
-
公开(公告)号:US4885283A
公开(公告)日:1989-12-05
申请号:US126643
申请日:1987-12-01
申请人: Michael J. Broadhurst , Balraj K. Handa , William H. Johnson , Geoffrey Lawton , Peter J. Machin
发明人: Michael J. Broadhurst , Balraj K. Handa , William H. Johnson , Geoffrey Lawton , Peter J. Machin
CPC分类号: C07K5/06191 , A61K38/00
摘要: The invention relates compounds of the formula ##STR1## wherein R.sup.1 -R.sup.5 and X have the significance given in the description, and their pharmaceutically acceptable salts. The compounds of formula I inhibit the enzyme collagenase and can be used in the form of medicaments for the control or prevention of degenerative joint diseases such as rheumatoid arthritis and osteoarthritis.
-
公开(公告)号:US5447929A
公开(公告)日:1995-09-05
申请号:US214895
申请日:1994-03-17
IPC分类号: A61K31/40 , A61K20060101 , A61K31/16 , A61K31/165 , A61K31/395 , A61K31/4015 , A61K31/403 , A61K31/4035 , A61K31/404 , A61K31/415 , A61K31/4166 , A61K31/4245 , A61K31/425 , A61K31/4427 , A61K31/445 , A61K31/495 , A61K31/496 , A61K31/50 , A61K31/53 , A61K31/535 , A61K31/536 , A61K31/5375 , A61K31/5377 , A61K31/54 , A61K31/55 , A61K33/08 , A61K38/00 , A61P9/10 , A61P29/00 , A61P35/00 , A61P43/00 , C07C20060101 , C07C259/10 , C07C317/44 , C07C323/04 , C07C333/24 , C07D20060101 , C07D207/26 , C07D207/27 , C07D207/40 , C07D207/404 , C07D207/408 , C07D209/18 , C07D209/48 , C07D211/88 , C07D233/72 , C07D233/74 , C07D233/96 , C07D239/52 , C07D239/54 , C07D239/88 , C07D249/12 , C07D253/06 , C07D271/06 , C07D271/07 , C07D295/18 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D407/06 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07D491/10 , C07D491/113 , C07K5/06 , C07K5/10 , C12N9/99
CPC分类号: C07D207/27 , C07D207/404 , C07D209/48 , C07D211/88 , C07D233/74 , C07D249/12 , C07D271/07 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D417/06 , C07D491/10
摘要: Hydroxamic acid derivatives of the fdrrnula ##STR1## and pharmaceutically acceptable salts thereof, which are collagenase inhibitors useful for the control or prevention of degenerative joint diseases, such as, rheumatoid arthritis and ostecarthritis or for the treatment of invasive tumours, atherosclerosis or multiple sclerosis, are described. Said compounds can be prepared either by hyclroxamidating a corresponding carboxylic acid or deprotecting a corresponding benzyloxycarbamoyl compound.
摘要翻译: 可以用于控制或预防退行性关节疾病例如类风湿性关节炎和骨关节炎或用于治疗侵入性肿瘤的胶原酶抑制剂,动脉粥样硬化或其它药学上可接受的盐, 多发性硬化症。 所述化合物可以通过将相应的羧酸环烷酰胺化或者使相应的苄氧基氨基甲酰基化合物脱保护来制备。
-
公开(公告)号:US5318964A
公开(公告)日:1994-06-07
申请号:US066832
申请日:1993-05-24
IPC分类号: A61K31/40 , A61K20060101 , A61K31/16 , A61K31/165 , A61K31/395 , A61K31/4015 , A61K31/403 , A61K31/4035 , A61K31/404 , A61K31/415 , A61K31/4166 , A61K31/4245 , A61K31/425 , A61K31/4427 , A61K31/445 , A61K31/495 , A61K31/496 , A61K31/50 , A61K31/53 , A61K31/535 , A61K31/536 , A61K31/5375 , A61K31/5377 , A61K31/54 , A61K31/55 , A61K33/08 , A61K38/00 , A61P9/10 , A61P29/00 , A61P35/00 , A61P43/00 , C07C20060101 , C07C259/10 , C07C317/44 , C07C323/04 , C07C333/24 , C07D20060101 , C07D207/26 , C07D207/27 , C07D207/40 , C07D207/404 , C07D207/408 , C07D209/18 , C07D209/48 , C07D211/88 , C07D233/72 , C07D233/74 , C07D233/96 , C07D239/52 , C07D239/54 , C07D239/88 , C07D249/12 , C07D253/06 , C07D271/06 , C07D271/07 , C07D295/18 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D407/06 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07D491/10 , C07D491/113 , C07K5/06 , C07K5/10 , C12N9/99
CPC分类号: C07D207/27 , C07D207/404 , C07D209/48 , C07D211/88 , C07D233/74 , C07D249/12 , C07D271/07 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D417/06 , C07D491/10
摘要: Hydroxamic acid derivatives of the formula ##STR1## and pharmaceutically acceptable salts thereof, which are collagenase inhibitors useful for the control or prevention of degenerative joint diseases, such as, rheumatoid arthritis and osteoarthritis or for the treatment of invasive tumors, atherosclerosis or multiple sclerosis, are described. Said compounds can be prepared either by hydroxamidating a corresponding carboxylic acid or deprotecting a corresponding benzyloxycarbamoyl compound.
摘要翻译: 式(I)的羟氨肟酸衍生物及其药学上可接受的盐,其是可用于控制或预防退行性关节疾病例如类风湿性关节炎和骨关节炎或用于治疗侵袭性肿瘤的胶原酶抑制剂,动脉粥样硬化或 多发性硬化症。 所述化合物可以通过将相应的羧酸异羟肟化或相应的苄氧基氨基甲酰基化合物脱保护来制备。
-
公开(公告)号:US5304549A
公开(公告)日:1994-04-19
申请号:US823212
申请日:1992-01-21
IPC分类号: A61K31/66 , A01N37/18 , A01N57/16 , A61K20060101 , A61K31/135 , A61P9/10 , A61P29/00 , C07C20060101 , C07C235/12 , C07C237/22 , C07C259/06 , C07C279/36 , C07C281/16 , C07D207/40 , C07D207/404 , C07D209/48 , C07D295/13 , C07D295/15 , C07F9/28 , C07F9/30 , C07F9/38 , C07F9/40 , C07F9/48 , C07F9/553 , C07F9/576 , C07F9/62 , C07F9/6558 , A61K31/16 , A61K31/185 , A61K31/675 , C07C259/04 , C07F9/06 , C07C93/10
CPC分类号: C07D207/404 , C07C237/22 , C07C259/06 , C07C279/36 , C07D209/48 , C07D295/13 , C07D295/15 , C07F9/301 , C07F9/4816 , C07F9/5537 , C07F9/5765 , C07F9/65583 , Y10S514/825
摘要: Compounds of the formula ##STR1## wherein A is the group ##STR2## R.sup.1 is hydrogen, amino, protected amino, acylamino or lower alkyl optionally substituted by aryl, hydroxy, protected hydroxy, amino, protected amino, acylamino, maleimido, succinimido, naphthalimido, 2,3-dihydro-1,3-dioxo-1H-benz[d,e]isoquinol-2-yl, carboxy, protected carboxy, carbamoyl, mono(lower alkyl)carbamoyl, di(lower alkyl)carbamoyl, di(lower alkyl)amino, carboxy-lower alkanoylamino, pyrrolidino or morpholino; R.sup.2 is hydrogen or lower alkyl optionally substituted by aryl, amino, protected amino, di(lower alkyl)- amino, guanidino, carboxyl, protected carboxyl, carbamoyl, mono(lower alkyl) carbamoyl, di(lower alkyl)carbamoyl, di(lower alkoxy)phosphinyl, dihydroxyphosphinyl, pyrrolidino, piperidino or morpholino; R.sup.3 is hydrogen or lower alkyl optionally substituted by hydroxy, protected hydroxy, amino or protected amino; R.sup.4 is hydrogen, hydroxy, lower alkoxy or benzyloxy; and R.sup.5 is hydrogen or halogen and their pharmaceutically acceptable salts, which are useful for the control or prevention of degenerative joint diseases or for the treatment of invasive tumors, atherosclerosis or multiple sclerosis are described.
摘要翻译: (*化学结构*)(I)的化合物其中A是基团(*化学结构*)(a)(*化学结构*)(b)R 1是氢,氨基,被保护的氨基,酰氨基或低级烷基, 被芳基,羟基,被保护的羟基,氨基,被保护的氨基,酰氨基,马来酰亚胺基,琥珀酰亚胺基,萘酰亚胺基,2,3-二氢-1,3-二氧代-1H-苯并(d,e)异喹啉-2-基,羧基, 保护的羧基,氨基甲酰基,单(低级烷基)氨基甲酰基,二(低级烷基)氨基甲酰基,二(低级烷基)氨基,羧基 - 低级烷酰基氨基,吡咯烷子基或吗啉代; 氨基,氨基,胍基,羧基,被保护的羧基,氨基甲酰基,单(低级烷基)氨基甲酰基,二(低级烷基)氨基甲酰基,二(低级) 烷氧基)氧膦基,二羟基氧膦基,吡咯烷子基,哌啶子基或吗啉代; R3是氢或任选被羟基,保护的羟基,氨基或被保护的氨基取代的低级烷基; R4是氢,羟基,低级烷氧基或苄氧基; 和R5是氢或卤素及其可用于控制或预防退行性关节疾病或用于治疗侵袭性肿瘤,动脉粥样硬化或多发性硬化的药学上可接受的盐。
-
公开(公告)号:US5614625A
公开(公告)日:1997-03-25
申请号:US417317
申请日:1995-04-05
IPC分类号: C07D401/06 , A61K20060101 , A61K31/16 , A61K31/40 , A61K31/41 , A61K31/415 , A61K31/4178 , A61K31/42 , A61K31/425 , A61K31/435 , A61K31/4427 , A61K31/445 , A61K31/454 , A61K31/535 , A61K31/5377 , A61K31/54 , A61K31/55 , A61P9/10 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07C20060101 , C07C259/04 , C07C259/06 , C07D207/36 , C07D209/48 , C07D233/72 , C07D233/74 , C07D249/12 , C07D263/30 , C07D263/44 , C07D271/07 , C07D291/06 , C07D403/06 , C07D413/06 , C07D417/06 , C07D487/04 , C07D491/113 , C07D401/08
CPC分类号: C07D209/48 , A61K31/4178 , A61K31/454 , A61K31/5377 , C07D233/74 , C07D263/44 , C07D401/06 , C07D403/06 , C07D417/06 , C07D487/04 , Y02P20/55
摘要: The invention provides hydroxamic acid derivatives of the general formula ##STR1## wherein R.sup.1 represents cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; R.sup.2 represents a saturated 5- to 8-membered monocyclic or bridged N-heterocyclic ring, which N-heterocyclic ring is attached via the N atom and when it is monocyclic, optionally contains NR.sup.4, O, S, SO or SO.sub.2 as a ring member and/or is optionally substituted on one or more C atoms by hydroxy, lower alkyl, lower alkoxy, oxo, ketalized oxo, amino, mono(lower alkyl)amino, di(lower alkyl)amino, carboxy, lower alkoxycarbonyl, hydroxy-methyl, lower alkoxymethyl, carbamoyl, mono(lower alkyl)-carbamoyl, di(lower alkyl)carbamoyl or hydroxyimino; R.sup.3 represents a 5- or 6-membered N-heterocyclic ring which (a) is attached via the N atom, (b) optionally contains N, O and/or S, SO or SO.sub.2 as an additional ring member, (c) is substituted by oxo on one or both C atoms adjacent to the linking N atom and (d) is optionally benz-fused or optionally substituted on one or more other C atoms by lower alkyl or oxo and/or on any additional N atom(s) by lower alkyl or aryl; R.sup.4 represents hydrogen, lower alkyl, aryl, aralkyl or a protecting group; m stands for 1 or 2 and n stands for 1-4, pharmaceutically acceptable salts thereof, intermediates used in the manufacture thereof, and methods of use therefor. Compounds of formula I are collagenase inhibitors useful in the control or prevention of degenerative joint diseases such as rheumatoid arthritis and osteoarthritis or in the treatment of invasive tumours, atherosclerosis or multiple sclerosis.
摘要翻译: 本发明提供通式为(I)的异羟肟酸衍生物,其中R 1表示环丙基,环丁基,环戊基或环己基; R2表示饱和的5-至8-元单环或桥连的N-杂环,N-杂环通过N原子连接,当其为单环时,任选地含有作为环成员的NR4,O,S,SO或SO2 羟基,低级烷基,低级烷氧基,氧代,缩酮化的氧代,氨基,单(低级烷基)氨基,二(低级烷基)氨基,羧基,低级烷氧基羰基,羟基 - 甲基 ,低级烷氧基甲基,氨基甲酰基,单(低级烷基) - 氨基甲酰基,二(低级烷基)氨基甲酰基或羟基亚氨基; (a)经由N原子连接的5-或6-元N-杂环,(b)任选地含有N,O和/或S,SO或SO 2作为另外的环成员,(c)是 在与连接的N原子相邻的一个或两个C原子上被氧代取代,(d)任选地被苯并稠合或任选地在一个或多个其它C原子上被低级烷基或氧代和/或任何另外的N原子取代, 由低级烷基或芳基取代; R4表示氢,低级烷基,芳基,芳烷基或保护基; m代表1或2,n代表1-4,其药学上可接受的盐,制备中使用的中间体及其用途。 式I化合物是可用于控制或预防变性关节疾病如类风湿性关节炎和骨关节炎或用于治疗浸润性肿瘤,动脉粥样硬化或多发性硬化的胶原酶抑制剂。
-
公开(公告)号:US4302398A
公开(公告)日:1981-11-24
申请号:US175724
申请日:1980-08-06
IPC分类号: C07C41/18 , C07C43/23 , C07C45/56 , C07D317/26 , C07F5/02 , C07C50/16 , C07C107/02
CPC分类号: C07F5/025 , C07C45/567 , C07D317/26
摘要: The present invention relates to naphthacene derivatives. More particularly, the invention is concerned with a process for the manufacture of hexahydronaphthacene derivatives and with certain of said derivatives per se. The invention is also concerned with novel intermediates occurring in said process and with the preparation thereof.There are presented hexahydronaphthacene derivatives of the formula ##STR1## wherein R.sup.1 represents a lower alkyl or esterified carboxy group or a group of the formula ##STR2## , in which R.sup.2 and R.sup.3 together form an oxo group or a protected oxo group and X represents a hydrogen atom or a hydroxy or acyloxy group, or--(CH.sub.2).sub.n --OY bin which n stands for 1 or 2 and Y represents a hydrogen atom or an alkyl or acyl group.Also presented are intermediates and a process to produce the compounds of formula I.
摘要翻译: 本发明涉及并四苯衍生物。 更具体地说,本发明涉及制备六氢萘并萘衍生物的方法以及某些所述衍生物本身。 本发明还涉及在所述方法和其制备中发生的新型中间体。 本发明提供下式的六氢萘并衍生物,其中R 1表示低级烷基或酯化羧基或下式的基团:其中R 2和R 3一起形成氧代基或被保护的氧代基,X代表 表示氢原子或羟基或酰氧基,或 - (CH 2)n -OY b,其中n表示1或2,Y表示氢原子或烷基或酰基。 还提出了产生式I化合物的中间体和方法。
-
公开(公告)号:US4409391A
公开(公告)日:1983-10-11
申请号:US318522
申请日:1981-11-05
IPC分类号: C07C39/17 , C07C41/26 , C07C43/21 , C07C43/23 , C07C45/56 , C07C46/00 , C07C49/563 , C07C49/573 , C07C49/577 , C07C49/755 , C07C50/10 , C07C50/22 , C07C50/32 , C07C50/36 , C07C50/38 , C07C62/34 , C07D319/08 , C07D339/06 , C07F5/02 , C07D317/72
CPC分类号: C07C62/34 , C07C39/17 , C07C41/26 , C07C45/56 , C07C46/00 , C07C49/563 , C07C49/573 , C07C49/577 , C07C49/755 , C07C50/10 , C07C50/22 , C07C50/32 , C07C50/36 , C07C50/38 , C07D319/08 , C07D339/06 , C07F5/025 , C07C2102/10
摘要: There is presented a process for the manufacture of hexahydronaphthacene derivatives of the general formula ##STR1## wherein one of R.sup.1 and R.sup.2 represents a hydrogen atom and the other represents a hydrogen atom or a hydroxy group or R.sup.1 and R.sup.2 together represent a protected oxo group, R.sup.3 represents a hydrogen atom or a hydroxy or acyloxy group and R.sup.4 represents a lower alkyl or esterified carboxy group or a group of the formula ##STR2## wherein R.sup.5 and R.sup.6 together form an oxo group or a protected oxo group and X represents a hydrogen atom or a hydroxy or acyloxy group or--(CH.sub.2).sub.n --OY bin which n stands for 1 or 2 and Y represents a hydrogen atom or an alkyl or acyl group.Also presented are certain of the novel derivatives per se and various novel intermediates in the process.
-
公开(公告)号:US4591636A
公开(公告)日:1986-05-27
申请号:US682448
申请日:1984-12-17
IPC分类号: C07D317/72 , C07D339/06 , C07F5/02 , C07H15/252
CPC分类号: C07D317/72 , C07D339/06 , C07F5/025 , C07H15/252
摘要: The invention relates to compounds of the formula ##STR1## wherein R is lower alkyl or a carboxy group or a group of the formula--(CH.sub.2).sub.n --OY a in which n stands for 1 or 2 and Y is hydrogen or alkyl and R.sup.Y and R.sup.z each are hydrogen or one of R.sup.Y and R.sup.z is hydrogen and the other is hydroxy,and pharmaceutically acceptable acid addition salts thereof.These compounds and salts possess antibiotic and antitumor activity and can be used as medicaments in the form of pharmaceutical preparations.
摘要翻译: 本发明涉及下式化合物其中R是低级烷基或羧基或式 - (CH 2)n -OY a的基团,其中n代表1或2,Y是氢或烷基, RY和Rz各自为氢或RY和Rz之一为氢,另一个为羟基,及其药学上可接受的酸加成盐。 这些化合物和盐具有抗生素和抗肿瘤活性,可用作药物制剂形式的药物。
-
公开(公告)号:US4393221A
公开(公告)日:1983-07-12
申请号:US318172
申请日:1981-11-04
IPC分类号: C07C39/17 , C07C41/26 , C07C43/21 , C07C43/23 , C07C45/56 , C07C46/00 , C07C49/563 , C07C49/573 , C07C49/577 , C07C49/755 , C07C50/10 , C07C50/22 , C07C50/32 , C07C50/36 , C07C50/38 , C07C62/34 , C07D319/08 , C07D339/06 , C07F5/02 , C07D317/72
CPC分类号: C07C62/34 , C07C39/17 , C07C41/26 , C07C45/56 , C07C46/00 , C07C49/563 , C07C49/573 , C07C49/577 , C07C49/755 , C07C50/10 , C07C50/22 , C07C50/32 , C07C50/36 , C07C50/38 , C07D319/08 , C07D339/06 , C07F5/025 , C07C2102/10
摘要: There is presented a process for the manufacture of hexahydronaphthacene derivatives of the general formula ##STR1## wherein one of R.sup.1 and R.sup.2 represents a hydrogen atom and the other represents a hydrogen atom or a hydroxy group or R.sup.1 and R.sup.2 together represent a protected oxo group, R.sup.3 represents a hydrogen atom or a hydroxy or acyloxy group and R.sup.4 represents a lower alkyl or esterified carboxy group or a group of the formula ##STR2## wherein R.sup.5 and R.sup.6 together form an oxo group or a protected oxo group and X represents a hydrogen atom or a hydroxy or acyloxy groupor ##STR3## in which n stands for 1 or 2 and Y represents a hydrogen atom or an alkyl or acyl group.Also presented are certain of the novel derivatives per se and various novel intermediates in the process.
-
-
-
-
-
-
-
-
-